HC Wainwright restated their buy rating on shares of Annovis Bio (NYSE:ANVS – Free Report) in a report released on Wednesday morning, Benzinga reports. They currently have a $30.00 target price on the stock.
Several other brokerages have also recently issued reports on ANVS. EF Hutton Acquisition Co. I raised shares of Annovis Bio to a “strong-buy” rating in a report on Tuesday, August 13th. Rodman & Renshaw reaffirmed a “buy” rating and set a $67.00 price objective on shares of Annovis Bio in a research report on Tuesday, July 2nd. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $33.60.
Check Out Our Latest Stock Analysis on Annovis Bio
Annovis Bio Price Performance
Annovis Bio (NYSE:ANVS – Get Free Report) last issued its quarterly earnings data on Thursday, August 15th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.19. Sell-side analysts expect that Annovis Bio will post -2.53 earnings per share for the current fiscal year.
Institutional Trading of Annovis Bio
A number of large investors have recently modified their holdings of the company. Redmond Asset Management LLC increased its position in Annovis Bio by 6.1% during the 1st quarter. Redmond Asset Management LLC now owns 36,157 shares of the company’s stock valued at $430,000 after purchasing an additional 2,077 shares during the period. Vanguard Group Inc. grew its stake in Annovis Bio by 6.1% during the 1st quarter. Vanguard Group Inc. now owns 357,942 shares of the company’s stock worth $4,260,000 after buying an additional 20,588 shares during the last quarter. Cetera Advisors LLC purchased a new stake in Annovis Bio in the first quarter valued at about $122,000. Greenwich Wealth Management LLC grew its stake in shares of Annovis Bio by 19.9% during the second quarter. Greenwich Wealth Management LLC now owns 15,075 shares of the company’s stock worth $87,000 after acquiring an additional 2,500 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in Annovis Bio in the 2nd quarter worth approximately $115,000. Hedge funds and other institutional investors own 15.83% of the company’s stock.
About Annovis Bio
Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.
Featured Articles
- Five stocks we like better than Annovis Bio
- Buy P&G Now, Before It Sets A New All-Time High
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- What is the Hang Seng index?
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- How to Use the MarketBeat Excel Dividend Calculator
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.